1510
Validation of the pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) in comparison with the insulin glargine u300 in the treatment of type 2 diabetes mellitus in the Russian Federation
The global pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) use in comparison with insulin glargine U300 in the treatment of type 2 diabetes mellitus, was validated. As the result, it was found that the model is relevant to local clinical practice, fully complies with the pharmacoeconomics methodology, takes into account the entire spectrum of costs relevant for the pharmacoeconomic evaluation of insulin in Russia, and the computations built in it is correct. Based on the actual cost data entered, the model calculated the ICER of degludec insulin, which was 214,714 rubles, which does not exceed the sum of three GDP per capita – 2,184,562 rubles and corresponds to the willingness to pay threshold in the Russian Federation. Thus, the insulin degludec (Tresiba®) can be considered as cost-effective from the standpoint of the conducted pharmacoeconomic analysis.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Serpik V.G., Kulikov A.Yu., Globin M.V., Litvinova A.A. Validation of the pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) in comparison with the insulin glargine u300 in the treatment of type 2 diabetes mellitus in the Russian Federation // Pharmacoeconomics: theory and practice. - 2021. - Vol.9, №3. - P.11-16 DOI: https://doi.org/10.30809/phe.3.2021.2
Comments0